NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
CCR4 inhibitor FLX475
An orally available, small molecule antagonist of C-C chemokine receptor type 4 (CCR4) with potential immunomodulatory and antineoplastic activities. Upon oral administration, FLX475 inhibits the binding of CCR4 to its signaling molecules, thereby blocking the recruitment of regulatory T cells (Tregs) to the tumor microenvironment (TME). This may abrogate the immunosuppressive effects of Tregs and promote an effective anti-tumor immune response. CCR4, a chemokine receptor normally expressed on circulating and tissue-resident T cells, is highly expressed on circulating Tregs and is associated with poor prognosis in certain cancers. Check for active clinical trials using this agent. (NCI Thesaurus)

Code name:FLX 475
FLX475
FLX-475